StockWatch
·

Global Health Ltd Q2 FY27 Results

MEDANTAQ2 FY27 Results
Filing
Result:Very Good· Market: Surged#Margin expansion#Record quarter#Broad based

Beat/Miss: Beat · Outlook: Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.5K12.7%33.6%
Total Income1.5K12.6%33.4%
Expenditure1.2K7.6%28.1%
PBT294.8338.3%47.5%
Net Profit219.1439.4%38.4%
OPM25.19%3.20pp2.73pp
NPM14.68%2.82pp0.52pp
EPS8.2138.9%39.4%
View full financials

Adjusted PAT growth (~54% ex one-off) with revenue at a 6-quarter high and margin expansion despite rising finance/depreciation costs is healthy and above-average for healthcare, but capex-driven leverage and a beat already priced via guidance cap it short of a clear standout.

MEDANTA · Q2 FY27 · THE VERDICT

The Margin Question Management Won't Answer

Medanta delivered strong headline growth—₹1,469 Cr revenue (+33.6% YoY), ₹219.1 Cr PAT (+38.3% YoY)—and proved Noida's unit economics work. But with >₹6,000 Cr of capex planned to add 3,450 beds, management conspicuously avoided forward margin guidance. Investors are betting growth can sustain without margin expansion—a question this quarter didn't resolve.

10 Nov 2026 · 6 min read
Q2 FY27 Revenue

₹1,469 Cr

+33.6% YoY

Operating EBITDA

₹370.1 Cr

+60% YoY, 25.2% margin

PAT

₹219.1 Cr

+38.3% YoY, 14.9% margin

Cluster 2 EBITDA margin

31.7%

vs Cluster 1 at 22%

Noida validates the model—but the real test is margin durability

Medanta delivered on the quarter. Consolidated revenue crossed ₹1,469 Cr (+33.6% YoY), profit grew 38.3%, and EBITDA margin stayed at 25.2% even as the company added 74 beds (to 3,115 total, +17% YoY). The headline win: Noida's 550-bed hospital hit EBITDA breakeven in Q2 FY27—roughly 1 year after inauguration and 1–2 quarters ahead of prior guidance (which called for H2 FY27 breakeven). That was the company's threshold for proving the new-market unit economics work. It crossed that bar.

The catch is Cluster 2's margin structure. Newer hospitals (Noida, Lucknow, Patna) delivered 31.7% EBITDA margin on ₹579 Cr revenue—a 10-percentage-point advantage over Cluster 1's 22%. That looks like operating leverage proving out. Dig deeper, and it's partly accounting: Cluster 2 bears zero corporate cost allocation; all overhead is charged to Cluster 1. Management acknowledged this directly on the call: 'Corporate costs all loaded on Cluster 1; Cluster 2 devoid of them, hence higher margin.' When Cluster 2 matures and takes on its share of corporate costs, blended margins will compress. But management volunteered no forward margin guidance. The implication is clear: they don't want to promise margin expansion when 3,450 beds are rolling out across six new geographies.

Q2 FY27 EBITDA margin
011.8323.6735.522Cluster 1 (mature)31.7Cluster 2 (new)25.2Blended (reported)
Cluster 2's 31.7% margin advantage is real but partly due to zero corporate cost loading. As new hospitals scale and absorb corporate allocations, blended margin will likely compress toward the mid-20% range.

Where the growth came from

Segment breakdown and volume drivers

Cluster 1 (Gurugram, Indore, Ranchi)

₹822.9 Cr
YoY Growth

+18% YoY

What drove it

Mature portfolio; procedurally heavy (Gurugram: 42 ORs, 7-8 cath labs). EBITDA ₹181 Cr (22% margin). Steady, not explosive.

Cluster 2 (Noida, Lucknow, Patna)

₹579 Cr
YoY Growth

+63% YoY

What drove it

Noida ramp-up; Lucknow/Patna stabilizing. Noida Q2: ₹105.9 Cr revenue, ₹8.6 Cr EBITDA (8.1% margin; breakeven achieved). Cluster 2 total EBITDA ₹183.7 Cr (31.7%).

International patients

₹99.3 Cr
YoY Growth

+30% YoY

What drove it

Strong FX headwind masked locally; indicates brand reach and case complexity.

OPD & Pharmacy

₹69.9 Cr
YoY Growth

+53% YoY

What drove it

Adjacency play; expanded to 17 pharmacy chains (from 8). Retail continuity-of-care strategy, not core margin driver.

Inpatient volumes are up 30% YoY, outpatient 38%, driving case throughput and occupancy. Average revenue per bed is stable (Noida +3% ARPB suggests price/case-mix holding), which means the growth is purely volume-driven—not tariff inflation. Management made this explicit on the call: 'Volumes drive growth, not tariff.' Occupancy on the expanded bed base is 67% (up from 64% a year ago), so there's still headroom to fill new beds as they come online.

What changed this call vs. prior guidance

Guidance updates
  • Capex raised: ₹4,850 Cr → >₹6,000 Cr over 4-5 years (vs. prior 3-4 years); +23% total, +3% bed count (3,350 → 3,450 beds)

  • Noida timeline accelerated: H2 FY27 → Q2 FY27 actual EBITDA breakeven; ~1 year post-launch

  • Guwahati size increased: 650 beds stated as new baseline, but no new capex number disclosed; implies higher investment than prior ₹9,700 Cr assumption

  • Margin guidance: Stayed mute. No forward revenue or PAT CAGR targets; focus remains volume-led growth with operating leverage 'as scale increases'

Management's claims vs. what holds up

Key call claims, fact-checked against result and prior guidance

Consolidated revenue ₹1,469 Cr (₹14,690 million), 34% YoY growth

Delivered result

Delivered ₹1,469 Cr, 33.6% YoY growth

Verdict

Supported (claimed 34%, actual 33.6%—rounding difference)

PAT ₹219.1 Cr (₹2,191 million), 38% YoY growth

Delivered result

Delivered ₹219.1 Cr, 38.3% YoY growth

Verdict

Supported (claimed 38%, actual 38.3%)

Operating EBITDA ₹370.1 Cr, 60% YoY growth at 25.2% margin

Delivered result

Delivered ₹370.1 Cr (₹3,701 million), 60% YoY growth, 25.2% margin

Verdict

Supported, all metrics precise

Noida achieved EBITDA breakeven within ~1 year of inauguration

Delivered result

Prior guidance: H2 FY27 breakeven. Actual: Q2 FY27 EBITDA ₹8.6 Cr on ₹105.9 Cr, ahead of schedule

Verdict

Supported, beat timing by 1-2 quarters

Inpatient volumes +30% YoY, outpatient +38% YoY

Delivered result

Consistent with consolidated +33.6% revenue growth; ARPB stable (+3%) suggests volumes, not pricing, drove growth

Verdict

Supported; volume-led growth confirmed

No forward margin guidance; focus on volume-led growth

Delivered result

Management declined to provide forward margin targets. Capex raised to >₹6,000 Cr but no target EBITDA margin stated.

Verdict

Supported; company actively avoiding margin commitments

The bull-bear ledger

  • Noida proof-of-concept: Achieved EBITDA breakeven in Q2 vs H2 prior guidance; validates rapid ramp model for new markets

  • Volume momentum strong: Inpatient +30%, outpatient +38%, occupancy 67% on expanded base; headroom to fill new beds

  • Balance sheet solid: Net cash ₹781.5 Cr (up from ₹590.6 Cr H1 start); comfortably funds >₹6,000 Cr capex over 4-5 years

  • Management execution credible: Hit FY27 revenue/PAT guidance; beat Noida timeline; track record of scaling (Gurugram built over 20+ years)

  • Cluster 2 margin sustainability unproven: 31.7% margin includes zero corporate cost loading; blended margin will compress as new hospitals mature

  • Capex execution risk: >₹6,000 Cr, 3,450 beds across six geographies (Delhi, Guwahati, Mumbai, Varanasi, Pitampura, Ghaziabad) over 4-5 years; delays already visible

  • No margin guidance: Conspicuous absence suggests management unsure of blended margin trajectory; avoiding downside surprise by not promising expansion

  • Regulatory headwind: Oncology drug margin caps (NCCPA proceedings) ongoing; unresolved at court and government level

Risks, ranked by how much they should concern a holder

Risk severity and why it matters

Margin mix evolution: Cluster 2 EBITDA margin 31.7% vs Cluster 1 22%. If new hospitals (Noida, Lucknow, Patna) don't sustain margins above blended average as they scale, operating leverage plateaus.

Medium–High

Stock valuation likely assumes margin expansion via operating leverage. Flattening margins would require growth to accelerate further to maintain EPS growth; unsustainable without pricing power (management says tariffs won't rise).

Capex execution: >₹6,000 Cr across six greenfield hospitals in multiple geographies over 4-5 years. South Delhi (GK) slowdown due to pollution norms; Varanasi drawing revisions; Pitampura delayed vs last guidance.

Medium

Delays reduce FY30 bed count target; slower revenue/EBITDA contribution than modeled. Balance sheet is strong, but execution risk in Tier 2 cities (land, approvals, clinical talent) is real and acknowledged.

Talent acquisition in Tier 2 markets: Guwahati, Lucknow, Patna, Varanasi require senior clinical talent and management. Management acknowledged slower hiring in non-Tier 1 towns.

Low–Medium

Slower ramp-up of new hospitals if clinical bench is thin; quality/reputation risk if hiring compromises. Noida model shows ability to build credibility; success not guaranteed across six parallel projects.

Oncology pricing regulation: NCCPA proceedings on drug margin caps ongoing at court and government levels. Oncology is high-margin; caps hit profitability directly.

Medium

Uncertainty on timeline and scope; unresolved since prior call. Medanta's diverse specialty mix (cardiac, orthopedic, procedural) hedges, but oncology revenue not disclosed separately.

Hospital-level metrics withheld: Management declined hospital-wise ARPP, occupancy, margin disclosure. Cites data granularity and timing issues.

Low

Limits analyst ability to triangulate unit economics and identify underperforming sites. Not a red flag (company may guard competitive info), but reduces transparency for margin mix validation.

How the street is positioned

The stock trades at ₹1,429.3, up 49.51% off its 52-week low (₹956) but -7.39% below its all-time high (₹1,543.4). It sits comfortably above its 20-day, 50-day, and 200-day moving averages (₹1,294, ₹1,370, ₹1,251 respectively), signaling an intact uptrend. RSI is at 64.9—overbought territory but not extreme. Volume is increasing, suggesting broad conviction behind the move.

What's telling is the institutional rotation. FII ownership has contracted sharply: from 11.54% in Q1 FY26 to 9.46% in Q1 FY27 (a 208-basis-point selldown). DII, by contrast, has accumulated aggressively: from 12.20% to 16.89% (469 basis points higher). The picture: foreign funds are rotating out; domestic institutions are buying the story. One bulk deal signals this shift: HDFC Mutual Fund bought 10 lakh shares at ₹1,225 from insider Sunil Sachdeva in May 2026—a redeployment at that price, now holding at a gain given the current ₹1,429.3 level.

The market is pricing in growth, but the FII exit into DII accumulation suggests caution on valuation or differential conviction in the thesis. The fading from ATH (down 7.39%) is not bearish but cautious—the market repriced growth expectations after the call. The stock is not cheap (up 49% off lows and near ATH signals full valuation), so the bull case must hold: execution on capex and sustained volume momentum. The margin question is precisely what could derail this—if Cluster 2 margins compress and capex slips, the stock faces re-rating downside.

The debate

What to watch next

Key catalysts and metrics
  • 1 · Cluster 2 margin trajectory (Q3 FY27 onwards)

    Watch for signs that Cluster 2 margins stay above 28-30% even as beds scale. If margins drop toward Cluster 1's 22%, blended EBITDA margin will compress and growth will need to accelerate to offset. This is the single most important watch; management needs to provide transparency here (hospital-wise metrics would help, but unlikely).

  • 2 · Greenfield project timelines (South Delhi GK, Guwahati, Mumbai, Varanasi)

    Track approvals, land acquisition, construction milestones. South Delhi is experiencing pollution-norms slowdown; Varanasi drawing revisions; Pitampura delayed. Delays push bed additions into FY29-FY30, reducing capex ROI timeline and delaying EBITDA breakevens. Any public updates on timelines in next call will signal confidence or slippage.

  • 3 · Oncology regulatory resolution (ongoing NCCPA proceedings)

    Oncology pricing margins remain uncertain. Any court verdicts or government guidance on NCCPA proceedings could unlock upside (if favorable) or create downside (if caps tighten). Not a Q3 catalyst likely, but a 2-3 quarter watch.

  • 4 · Hospital-level metrics disclosure (voluntary)

    Management has withheld Noida, Lucknow, Patna occupancy/ARPP details. If disclosed in Q3 call or investor presentations, investors can triangulate margin sustainability. Lack of disclosure is a yellow flag on transparency.

The rating and the track

Buy, with eyes on execution. Medanta delivered a solid quarter and proved Noida works. The capex raise to >₹6,000 Cr signals confidence, and the balance sheet is fortress. But the market has priced in margin expansion, and management's silence on forward margin guidance suggests they're not certain they can deliver it. For investors, this is a volume-and-execution play, not a margin-expansion play. Watch capex timelines closely; if Cluster 2 margins stay above 28% as hospitals scale, the bull case holds. If margins compress faster than expected, the stock re-rates. The number to track from here is the blended EBITDA margin; if it stays in the 24-26% range over the next 4-5 quarters despite 3,450 beds of new capacity coming online, management has earned the benefit of the doubt. If it falls below 23%, the thesis cracks.

Medanta is not a step-change story; it's a steady-execution one. Noida validates the model, but execution risk is real—six hospitals, four geographies, >₹6,000 Cr capex, Tier 2 talent acquisition, regulatory uncertainty on oncology. The stock has run 49% off lows and is now fully valued. Holders should monitor capex progress quarterly and press for hospital-level margin disclosure in the next call. The upside case holds if margins stay elevated; the downside is sharp if they compress and capex slips.

Informational and educational content only. Not investment advice.